ArticleCancer management and research2025

Durable Control of Multi-Refractory HBV-HCC with Bevacizumab/Sintilimab/Lenvatinib Triplet Therapy.

Jian Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.